Written and maintained by CASRAI Editorial Board
Published
On this page
The Center for Medicinal Cannabis Research (CMCR), based at the University of California San Diego (UC San Diego), is the pioneer state-sponsored academic research center in the United States dedicated to conducting rigorous clinical trials, preclinical investigations, and analytical studies on the therapeutic efficacy and health effects of cannabis and cannabinoid compounds. Established in 2000 by the California State Legislature pursuant to California Senate Bill 847, the CMCR coordinates statewide multidisciplinary research evaluating cannabinoid pharmacology, operates specialized clinical inhalation and driving simulation laboratories, oversees an independent state reference testing facility, and administers competitive research grants funded through California Proposition 64 cannabis tax revenues.
This page describes products and general use; it is not medical advice.
What the Center for Medicinal Cannabis Research Is
The Center for Medicinal Cannabis Research represents the longest-operating state-authorized clinical cannabis research facility in the United States. Following the 1996 passage of California Proposition 215 (the Compassionate Use Act), which legalized the medical use of cannabis under state law, significant scientific uncertainty remained regarding clinical efficacy, dosing parameters, adverse reactions, and cannabinoid pharmacokinetics. In response, the California State Legislature enacted Senate Bill 847 (SB 847, authored by Senator John Vasconcellos) in 1999, which was signed into law by Governor Gray Davis and codified in California Health and Safety Code Section 11362.9. This statutory mandate formally directed the University of California to establish an objective, university-wide medical cannabis research initiative tasked with evaluating whether cannabis preparations provided safe and verifiable therapeutic utility.
In 2000, UC San Diego was selected to house and administer the statewide center. During its initial operating decade, the CMCR launched the first therapeutic clinical trials of inhaled cannabis conducted in the United States in over twenty years. Operating under rigorous federal investigational protocols, the center established baseline clinical evidence regarding short-term cannabinoid administration for refractory neuropathic pain conditions and muscle spasticity associated with multiple sclerosis. These foundational studies challenged longstanding regulatory presumptions by demonstrating quantifiable clinical responses under randomized, double-blind, placebo-controlled clinical trial designs.
The institutional mandate of the CMCR expanded substantially following the passage of California Proposition 64 (the Adult Use of Marijuana Act) in November 2016. Codified in California tax statutes, Proposition 64 established a dedicated statutory allocation directing annual public cannabis excise tax revenues to the UC San Diego center to fund continuous research into the efficacy and adverse consequences of cannabis and its constituent cannabinoids. With this permanent funding mechanism, the center transitioned from an ad hoc project center into a permanent university institute that combines in-house clinical trials, an analytical reference testing laboratory, a central biological specimen repository, and a competitive statewide grants program.
In scholarly literature, medical research registries, and state government publications, the facility is designated under several recognizable variants. It is widely referenced as the UC San Diego CMCR (or UCSD CMCR), reflecting its institutional campus location within the School of Medicine. In international academic collaborations, policy reviews across Europe and the Commonwealth, and comparative regulatory literature, the organization is frequently indexed under the British orthographic variant, Centre for Medicinal Cannabis Research. Regardless of regional spelling, all operational designations refer to the unified statutory research platform headquartered at UC San Diego.
Who Runs It and What It Covers
The operational administration of the Center for Medicinal Cannabis Research is structured around an integrated governance model that combines senior academic clinicians, neuroscientists, analytical toxicologists, and regulatory specialists. Executive leadership is headed by Founding Director Igor Grant, MD, a Distinguished Professor of Psychiatry at UC San Diego with extensive expertise in neuropsychiatry, HIV-associated neurocognitive disorders, and clinical trial design. The center is co-directed by J. Hampton Atkinson, MD, an authority on chronic pain psychopharmacology, and Thomas Marcotte, PhD, a Professor of Psychiatry whose empirical investigations focus on driving impairment, neurocognitive functioning, and behavioral pharmacology following cannabis administration.
Medical and laboratory oversight is distributed across dedicated operational units. David Grelotti, MD, serves as the CMCR Medical Director, supervising human subjects safety protocols, clinical intake, and adverse event reporting. Laboratory medicine and bioanalytical toxicological investigations are coordinated through the Analytical Chemistry Laboratory under the direction of Robert L. Fitzgerald, PhD, DABCC, who also directs the Clinical Chemistry Laboratory at UC San Diego Health. Research operations, multi-site study coordination, and regulatory compliance are directed by Jennifer Marquie-Beck, MPH. The center’s strategic initiatives are informed by a National Advisory Council comprising academic investigators, clinical toxicologists, and public health officials from institutions across North America.
Specialized Research Laboratories and Technical Infrastructure
The technical capabilities of UCSD CMCR encompass highly specialized physical facilities designed to overcome the logistical and regulatory complexities inherent in cannabinoid clinical research:
- Negative-Pressure Inhalation Administration Suites: Administering smoked or vaporized botanical cannabis within a clinical trial requires specialized atmospheric containment to protect clinical staff and research facilities from secondhand smoke exposure. The CMCR operates custom-engineered negative-pressure administration rooms equipped with dedicated high-efficiency particulate air (HEPA) filtration systems and continuous air-exchange monitoring, enabling controlled human pulmonary drug delivery in compliance with hospital environmental safety standards.
- Advanced Driving Simulation and Cognitive Suites: To evaluate real-world public safety and psychomotor impairment, the center houses advanced driving simulation laboratories. These facilities utilize dynamic driving simulators linked to multi-camera eye-tracking equipment and synchronized physiological monitors. Investigators measure lane departure frequency, reaction times, divided-attention processing, and standard deviations of lateral position to establish objective correlations between biological cannabinoid levels and functional driver impairment.
- Mobile Testing Laboratory Unit: A major challenge in cannabinoid research is the federal regulatory barrier that prevents schedule-controlled research facilities from administering commercially available dispensary products. To study real-world products consumed by the public, the CMCR deploys an advanced mobile research unit. This specialized vehicle travels to community settings, allowing researchers to collect biological specimens and conduct cognitive testing immediately before and after participants administer their own legally purchased state-regulated products.
- CMCR Reference Laboratory: Established in 2021 through an interagency agreement with and funded by the California Department of Cannabis Control (DCC), the CMCR Reference Laboratory operates as an independent university testing and method-development facility. Directed by Jeremiah Momper, PharmD, PhD, and Raymond Suhandynata, PhD, the laboratory develops validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) methodologies. The Reference Lab tests commercial cannabis goods purchased from licensed dispensaries across California, validating the testing accuracy of commercial laboratories and ensuring strict adherence to state contamination limits for residual solvents, heavy metals, microbial pathogens, and 64 distinct agricultural pesticides. These validation standards align directly with industrial compliance guides such as cannabis testing requirements and international solvent control benchmarks such as ICH Q3C residual solvent guidelines.
- Centralized Biospecimen and Data Repository: The center maintains a comprehensive biorepository that archives biological samples collected across completed and ongoing trials. Preserved specimens include whole blood, plasma, serum, oral fluid, exhaled breath condensate, cerebrospinal fluid (CSF), urine, and fecal samples. The repository utilizes 24-hour continuous temperature-monitored ultra-low cryogenic freezers and an automated web-based tracking inventory system, allowing researchers to conduct cross-study biomarker analyses, longitudinal pharmacokinetic modeling, and metabolomic evaluations.
Clinical Research Scope and Disease Targets
The substantive research portfolio of the CMCR spans basic endocannabinoid neurobiology, controlled clinical pharmacology, and epidemiological health outcomes. Within clinical therapeutics, the center has conducted randomized trials evaluating inhaled and oral cannabinoids for refractory central and peripheral neuropathic pain, including painful diabetic neuropathy, spinal cord injury dysesthesia, and HIV sensory neuropathy. Research has systematically explored the pharmacological properties of minor phytocannabinoids, such as cannabigerol (CBG), cannabichromene (CBC), and cannabidiol (CBD), alongside the modulation of cannabinoid receptor 1 (CB1) activity by secondary botanical terpenes like beta-myrcene. Botanical characterization and phytochemical identification in these programs trace to scientific methodologies published in specialized botanical chemistry resources, including the Journal of Natural Products and established safety indices such as the Botanical Safety Handbook.
Beyond analgesia, CMCR programs investigate psychiatric and neurodevelopmental conditions, including adjunct cannabidiol administration for early-phase psychosis, severe anorexia nervosa mealtime anxiety, and alcohol and prescription opioid use disorders. Mechanistic studies investigate inflammatory biomarkers, blood-brain barrier permeability in neurodegenerative conditions, and gastrointestinal barrier integrity. Public safety research coordinated with the California Highway Patrol (CHP) and the California Office of Traffic Safety (OTS) examines field sobriety testing reliability, providing evidence-based data that informs state legislative policy.
How to Access and Use CMCR Research Resources
Researchers, academic faculty, and clinical investigators seeking to collaborate with the Center for Medicinal Cannabis Research or utilize its grant mechanisms must navigate an established multi-stage administrative and regulatory pathway. Because cannabis research involves Schedule I controlled substances under federal law alongside state-regulated commercial frameworks, access requires rigorous compliance with university, state, and federal oversight bodies.
The following numbered steps outline the operational procedure for accessing CMCR funding mechanisms, specialized research laboratories, and shared institutional data:
- Review Current Request for Applications (RFA) Deadlines: Investigators must monitor the official CMCR Grants Program portal for active solicitations. The center offers two primary funding tiers: Primary Project Awards, which provide up to $825,000 in total direct and indirect costs over a three-year project period ($275,000 annually), and Pilot Project Awards, which allocate up to $300,000 over two years ($150,000 annually). Eligibility is strictly restricted to principal investigators holding academic appointments at accredited public or private California universities and nonprofit biomedical research institutes.
- Submit Formal Letters of Intent and Grant Proposals: Applicants must submit an initial Letter of Intent (LOI) outlining specific aims, preliminary data, clinical or basic science methodology, and preliminary budget calculations via the center’s electronic grants portal. Approved LOIs are invited to submit full scientific applications, which undergo an independent peer-review evaluation modeled on National Institutes of Health (NIH) study section criteria, scoring significance, scientific rigor, innovation, investigator qualifications, and feasibility.
- Obtain Institutional and State Approvals (IRB and RAPC): Following grant selection or protocol development, investigators must secure approval from their local Institutional Review Board (IRB) for human subjects protections. In California, protocols administering cannabis must also obtain statutory clearance from the Research Advisory Panel of California (RAPC), an independent state regulatory body that reviews human and animal research protocols involving controlled substances.
- Secure Federal Schedule I Registration and FDA IND Clearance: For studies administering botanical cannabis or isolated cannabinoids not yet approved for commercial prescription use, investigators must file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and obtain an individual Schedule I researcher registration license from the Drug Enforcement Administration (DEA). This process involves rigorous facility inspections, secure vault storage verification, and continuous inventory tracking protocols.
- Coordinate Drug Supply and Analytical Characterization: Investigational cannabis products must be procured through federally authorized channels, such as the National Institute on Drug Abuse (NIDA) Drug Supply Program, or compliant DEA-licensed bulk manufacturers producing botanical drug substances under Current Good Manufacturing Practice (cGMP). CMCR analytical chemists coordinate certificate of analysis (COA) verification to confirm cannabinoid concentration profiles, terpene content, and absence of heavy metals or agrochemical residues.
- Execute Protocols via Shared Facilities or Biorepository Access: Investigators approved to use UC San Diego physical facilities coordinate operational scheduling with the CMCR Director of Research Operations. Studies requiring environmental containment utilize the negative-pressure inhalation rooms, while behavioral studies access the driving simulation laboratory. Investigators conducting secondary analyses submit data and specimen access requests to the CMCR Scientific Review Committee to obtain de-identified clinical datasets or biobank specimens for biomarker and genomic discovery.
Collaborative scientific data generated across CMCR-supported trials are integrated into national regulatory archives, aligning with toxicological evaluation protocols established across federal facilities like the National Center for Toxicological Research.
Strengths and Operational Limits
The Center for Medicinal Cannabis Research offers distinctive operational and scientific advantages that establish it as a premier national academic platform, while operating under unavoidable regulatory and geographic boundaries.
Core Institutional Strengths
- Longitudinal Clinical Expertise: Operating continuously since 2000, CMCR possesses over two decades of institutional experience executing double-blind, placebo-controlled clinical trials with controlled botanical materials. This institutional track record provides validated clinical outcome batteries, standardized inhalation dosing protocols, and established safety parameters.
- Dedicated Public Funding Model: Unlike private research foundations or commercial research programs, the CMCR is funded directly through state legislative appropriations and Proposition 64 tax allocations. This guarantees complete financial independence from commercial cannabis cultivators, processors, and retailers, ensuring scientific objectivity, public credibility, and uncompromised regulatory reporting.
- Integrated Bench-to-Bedside and Mobile Facilities: By combining negative-pressure clinical administration suites, mobile community testing laboratories, the DCC-funded Reference Laboratory, and an ultra-low temperature biobank, the center provides a comprehensive infrastructure spanning basic pharmacology, clinical efficacy, and commercial product safety.
- High-Impact Policy Influence: Findings generated by CMCR investigators have directly informed international, federal, and state policy. CMCR faculty served as authors and reviewers on the landmark National Academies of Sciences, Engineering, and Medicine (NASEM) consensus report, presented expert evidence at FDA cannabidiol public hearings, and provided technical guidance to the California Highway Patrol, the Medical Board of California, and the California Department of Cannabis Control.
Operational Boundaries and Constraints
- Federal Regulatory Burdens: Because botanical cannabis remains classified as a Schedule I controlled substance under the federal Controlled Substances Act (CSA), research protocols face complex multi-jurisdictional oversight. Researchers must obtain multiple concurrent approvals from the DEA, FDA, state RAPC, and institutional IRBs, creating multi-month administrative onboarding periods before clinical trials can commence.
- Jurisdictional Restrictions on Grant Allocations: Funding allocated through the CMCR Grants Program is derived from California tax revenues and is statutorily restricted to investigators based at California institutions. While academic researchers from out-of-state universities can collaborate on multi-center manuscripts or analyze de-identified public data products, they cannot serve as primary awardees of CMCR grant funds.
- Supply Disconnect Between Federal and Commercial Products: Under federal investigational guidelines, clinical trials have historically been required to use standardized drug supplies from federally contracted suppliers, which often possess differing cannabinoid and terpene compositions compared to the highly potent botanical extracts, concentrates, and edibles sold in commercial state-licensed dispensaries. The CMCR mobile laboratory addresses this gap observationally, but randomized controlled trials remain constrained by federal drug supply licensing frameworks.
Alternatives and Complementary Research Programmes
While the Center for Medicinal Cannabis Research at UC San Diego represents the pioneer state-funded clinical cannabis center in the United States, several academic institutions and specialized public programs have developed complementary cannabis research centers. These entities differ across authorizing legislative mandates, core disciplinary orientations, funding structures, and laboratory capabilities.
The table below compares the Center for Medicinal Cannabis Research with prominent university-affiliated cannabis research centers across the United States:
| Institution & Center | Host University & Jurisdiction | Statutory Mandate & Primary Funding | Core Laboratory & Clinical Capabilities | Primary Disciplinary Focus |
|---|---|---|---|---|
| Center for Medicinal Cannabis Research (CMCR) | University of California San Diego (California) | California SB 847 (1999) & Proposition 64 tax revenues; DCC state grants | Negative-pressure inhalation suites, driving simulation, mobile testing lab, DCC Reference Lab, biobank | Controlled human clinical trials, neuropathic pain, driving impairment, state regulatory testing |
| Institute of Cannabis Research (ICR) | Colorado State University Pueblo (Colorado) | Colorado HB 19-1311 (2019); Colorado Marijuana Tax Cash Fund | Analytical chemistry suites, agricultural growth facilities, hemp extraction laboratories | Multidisciplinary research, agronomy, industrial hemp genetics, sponsor of *Journal of Cannabis Research* |
| Consortium for Medical Marijuana Clinical Outcomes Research (COMMCOR) | University of Florida (Florida) | Florida Statute 1004.4351; state medical marijuana trust allocations | Clinical registry platforms (MEMORY), biostatistical core, multi-institutional clinical network | Observational clinical outcomes, medical marijuana patient registry data, real-world health outcomes |
| Center for Cannabis and Cannabinoids | University of California Los Angeles (California) | Jane and Terry Semel Institute / David Geffen School of Medicine; academic & CMCR grants | Neuroimaging suites, psychopharmacological testing, basic neuroscience laboratories | Addiction biology, cannabinoid analgesia, psychiatric interactions, neuroimaging |
| National Center for Natural Products Research (NCNPR) | University of Mississippi (Mississippi) | Federal USDA / NIDA contract; federal research appropriations | Agricultural cultivation farms, industrial extraction pilot plants, botanical repository | Agricultural cultivation, supply of federal research cannabis (historical monopoly), botanical standardization |
The data table below provides a comprehensive tabular ledger of all 24 CMCR Grant Awards allocated between 2019 and 2026 under California Proposition 64, detailing awarded amounts, principal investigators, host institutions, and study titles.
Sources
- Center for Medicinal Cannabis Research: General CMCR Information, checked 2026-11-22
- Center for Medicinal Cannabis Research: CMCR Reference Lab, checked 2026-11-22
- Center for Medicinal Cannabis Research: CMCR Grants Program, checked 2026-11-22
- Center for Medicinal Cannabis Research: Mission, checked 2026-11-22
- U.S. Food and Drug Administration: FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), checked 2026-11-22
- Colorado State University Pueblo: Institute of Cannabis Research, checked 2026-11-22
- BioMed Central: Journal of Cannabis Research Aims and Scope, checked 2026-11-22
Data: Center for Medicinal Cannabis Research (CMCR) California State Grant Awards (2019-2026)
Comprehensive ledger of 24 primary and pilot research studies funded by the Center for Medicinal Cannabis Research (CMCR) at UC San Diego under California Proposition 64 research allocations between 2019 and 2026. Compiled directly from official CMCR Grants Program documentation, tracking study titles, award years, principal investigators, recipient academic institutions, grant award tiers, and awarded funding amounts in US dollars.
Period covered: 2019-2026. Coverage: California, United States.
| Study Title | Award Year | Principal Investigator | Host Institution | Award Tier | Award Amount (USD) |
|---|---|---|---|---|---|
| Cannabinoid alteration of the reinforcing effects of exercise in rats | 2026 | Michael Taffe, PhD | UC San Diego | Pilot Project Award | 300000 |
| Vaporized cannabis flower for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial with open-label extension | 2026 | Nathaniel Schuster, MD | UC San Diego | Primary Project Award | 825000 |
| Analgesic and subjective effects of cannabichromene administered alone and in combination with delta-9 tetrahydrocannabinol | 2025 | Ziva Cooper, PhD | UCLA | Primary Project Award | 825000 |
| Therapeutic potential of cannabinoids for cocaine relapse | 2025 | Natalie Zlebnik, PhD | UC Riverside | Pilot Project Award | 300000 |
| Evaluating the impact of perioperative cannabidiol exposure in a preclinical model of orthopaedic implant infections | 2024 | Nicholas Bernthal, MD | UCLA | Pilot Project Award | 300000 |
| Myrcene modulates on CB1 receptor function via enhancement of endocannabinoids | 2024 | Catherine Cahill, PhD | UCLA | Pilot Project Award | 300000 |
| Sex differences in cannabidiol's effects on blood pressure in normotensive and hypertensive conditions | 2024 | Zhi-Ling Guo, MD, PhD | UC Irvine | Pilot Project Award | 300000 |
| Cannabidiol use during pregnancy: Safety and risk for the developing fetus | 2024 | Jennifer Thomas, PhD | San Diego State University | Pilot Project Award | 300000 |
| Evaluating the efficacy of cannabidiol for reducing cigarette use | 2023 | Edythe London, PhD | UCLA | Primary Project Award | 825000 |
| Contribution of genetic factors to individual differences in anxiety in response to the cannabinoids THC and CBD | 2023 | Jamie Inman, PhD | Lawrence Berkeley National Laboratory | Pilot Project Award | 300000 |
| The effects and brain mechanisms supporting cannabis-induced chronic low back pain relief | 2023 | Fadel Zeidan, PhD | UC San Diego | Pilot Project Award | 300000 |
| A clinical trial of a hemp-derived, ultra-high cannabidiol product for anxiety and pain in glioblastoma patients | 2022 | Nicholas Butowski, MD & Staci Gruber, PhD | UC San Francisco | Pilot Project Award | 300000 |
| Terpenes as novel analgesics - preclinical study | 2022 | Catherine Cahill, PhD | UCLA | Pilot Project Award | 300000 |
| Antinociceptive effects of phytocannabinoids in a mouse model of sickle cell disease (SCD) | 2022 | Daniele Piomelli, PhD | UC Irvine | Pilot Project Award | 400000 |
| The effects of THC on glucose metabolism and endothelial function in subjects with type 2 diabetes | 2021 | Jeremy Pettus, MD | UC San Diego | Primary Project Award | 825000 |
| Impact of cannabis expose on gut barrier function in health and disease | 2021 | Nicholas DiPatrizio, PhD | UC Riverside | Pilot Project Award | 300000 |
| Therapeutic efficacy of cannabis and cannabinoids in prescription opioid abuse and addiction | 2021 | Michael Taffe, PhD | UC San Diego | Pilot Project Award | 300000 |
| Analgesic, appetite-stimulating, and subjective effects of cannabigerol administered alone and in combination with delta-9tetrahydrocannabinol | 2020 | Ziva Cooper, PhD | UCLA | Primary Project Award | 825000 |
| Effects of CBD on blood pressure and substrate metabolism during metabolic syndrome | 2020 | Rudy M. Ortiz, PhD | UC Merced | Pilot Project Award | 300000 |
| Effects of cannabidiol (CBD) versus placebo as an adjunct to treatment in early psychosis: Understanding the mechanism and mediators of action | 2019 | Kristin Cadenhead, MD | UC San Diego | Primary Project Award | 825000 |
| Therapeutic response of cannabidiol in rheumatoid arthritis | 2019 | Veena Ranganath, MD | UCLA | Primary Project Award | 825000 |
| Cannabidiol for sedative/hypnotic-sparing management of insomnia in adults | 2019 | Mariana Cherner, PhD | UC San Diego | Primary Project Award | 825000 |
| Cannabidiol as a strategy to treat alcohol dependence | 2019 | Giordano de Guglielmo, PharmD, PhD | UC San Diego | Pilot Project Award | 300000 |
| The role of cannabidiol (CBD) in regulating meal time anxiety in anorexia nervosa: Safety, tolerability and pharmacokinetics | 2019 | Guido Frank, MD | UC San Diego | Pilot Project Award | 300000 |
Sources
- CMCR Grants Program (accessed 2026-11-22)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







